Can stem cell boost, treadmill use improve artery disease?

November 1, 2011

(Medical Xpress) -- Northwestern Medicine researchers have launched a clinical trial testing a new combination of treadmill exercise and drug regimen to see if the two together improve the walking ability of people with peripheral arterial disease (PAD) more than either therapy individually. Scientists are studying if a combination of walking and the medication together increase the production of a participant's own stem cells, and, ultimately, the development of greatly needed new blood vessels in the calf muscles.

People with PAD -- about 8 million in the United States -- develop in their that slow or stop the blood flood flow to their legs. As a result, they have pain and difficulty walking even short distances. Few effective therapies are available to prevent mobility loss in patients with PAD.

"This is a painful, disabling disease," said lead investigator Mary McDermott, M.D., professor of medicine at Northwestern University Feinberg School of Medicine and a physician at Northwestern Memorial Hospital. "Many people with PAD have to restrict their activities and can't do such basic things as going grocery shopping or on a family outing because it hurts too much to walk."  

"This study is particularly important because there really isn't any good treatment to help these people," McDermott added.

In the National Institutes of Health-funded trial, Northwestern Medicine researchers will give participants subcutaneous injections of a drug that boosts the level of circulating , called progenitor stem cells. These circulating stem cells can help form new to the legs that improve blood flow to calf skeletal muscle and potentially improve walking ability in people with PAD. People with PAD have lower levels of circulating progenitor stem cells than individuals who do not have it.

In addition to the primary goal of determining whether the dual therapies are most effective, the study also will provide new information about how walking and the drug therapy individually affect artery health throughout the body as well as changes in the stem cell levels over time.

Preliminary evidence from previous studies shows that increasing the circulating levels of the progenitor stem cells may improve walking ability in people with PAD. Three previous small have tested whether a medication, granulocyte macrophage colony stimulating factor (GM-CSF), which increases circulating levels of these stem cells, improves walking ability in people with PAD. These previous studies have yielded mixed results. Whether GM-CSF can improve walking ability in patients with PAD is not definitively established.

Preliminary evidence also suggests that walking exercise may help to stimulate increases in circulating levels of stem cells and encourage their deposition in that are affected by PAD.

The new randomized, controlled clinical trial is the first to test whether the combination of GM-CSF and supervised exercise can improve walking ability better than GM-CSF alone or supervised exercise alone in patients with PAD.  The trial will include 240 participants with PAD who will be randomized to one of four study arms: a) GM-CSF and supervised exercise therapy; b) GM-CSF therapy and weekly health education sessions; c) placebo and supervised exercise therapy; and d) placebo and health education sessions. Study participants will be followed for six months. The study seeks to recruit 240 participants.

Explore further: Interventional radiologists: Learn about peripheral arterial disease and get moving

Related Stories

Interventional radiologists: Learn about peripheral arterial disease and get moving

September 6, 2011
Peripheral arterial disease, or PAD, is a common condition affecting 12-20 percent of Americans age 65 and older that may be a signal of future heart attack and stroke -- and many with the disease may be unaware they have ...

Recommended for you

Five vascular diseases linked to one common genetic variant

July 27, 2017
Genome-wide association studies have implicated a common genetic variant in chromosome 6p24 in coronary artery disease, as well as four other vascular diseases: migraine headache, cervical artery dissection, fibromuscular ...

Could aggressive blood pressure treatments lead to kidney damage?

July 18, 2017
Aggressive combination treatments for high blood pressure that are intended to protect the kidneys may actually be damaging the organs, new research from the University of Virginia School of Medicine suggests.

Quantifying effectiveness of treatment for irregular heartbeat

July 17, 2017
In a small proof-of-concept study, researchers at Johns Hopkins report a complex mathematical method to measure electrical communications within the heart can successfully predict the effectiveness of catheter ablation, the ...

Concerns over side effects of statins stopping stroke survivors taking medication

July 17, 2017
Negative media coverage of the side effects associated with taking statins, and patients' own experiences of taking the drugs, are among the reasons cited by stroke survivors and their carers for stopping taking potentially ...

Study discovers anticoagulant drugs are being prescribed against safety advice

July 17, 2017
A study by researchers at the University of Birmingham has shown that GPs are prescribing anticoagulants to patients with an irregular heartbeat against official safety advice.

Protein may protect against heart attack

July 14, 2017
DDK3 could be used as a new therapy to stop the build-up of fatty material inside the arteries


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.